Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Table 4 Mortality from 9 March 2006 to 1 January 2015 in patients with rheumatoid arthritis who received alemtuzumab between 1991 and 1994

Age at death, years	Cause of death
78	Carcinomatosis, unknown primary, rheumatoid arthritis
79	Bronchopneumonia, rheumatoid arthritis, cellulitis
58	Respiratory failure, pulmonary oedema
89	Bronchopneumonia, congestive cardiac failure
77	Pneumonia, vascular dementia
71	Brain tumour
76	Sepsis, urinary tract infection, chronic obstructive pulmonary disease, rheumatoid arthritis
69	Adenocarcinoma of the lung
79	Pulmonary fibrosis
75	Dementia, rheumatoid arthritis

ISSN: 1478-6362